Dalton, Harry R.
Kamar, Nassim
van Eijk, Jeroen J. J.
Mclean, Brendan N.
Cintas, Pascal
Bendall, Richard P.
Jacobs, Bart C.
Article History
First Online: 29 December 2015
Competing interests
: H.R.D. has received travel and accommodation costs and consultancy fees from GlaxoSmithKline, Wantai and Roche; travel, accommodation and lecture fees from Merck, Gilead and GFE Blut; and travel and accommodation fees from the Falk Foundation. N.K. has received travel and accommodation costs and consultancy fees from Novartis and Merck; travel, accommodation and lecture fees from Gilead, Novartis, Astellas, BMS, Amgen and Fresenius. J.J.J.v.E. has received travel and accommodation costs or consultancy or lecture fees from Merck, Biogen Idec, Novartis and Teva Pharmaceutical Industries. B.C.J. has received research support from Prinses Beatrix Spierfonds, CSL-Behring and Grifols, and travel support from Baxter Biopharmaceutics. The other authors declare no competing interests.